Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for MGTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 133.89M
March 31, 2026 -10.11M
December 31, 2025 5.328M
September 30, 2025 -0.219M
June 30, 2025 5.45M
March 31, 2025 1.713M
December 31, 2024 4.244M
September 30, 2024 49.96M
June 30, 2024 1.603M
March 31, 2024 -1.27M
December 31, 2023 27.71M
September 30, 2023 -0.404M
June 30, 2023 57.95M
March 31, 2023 -1.231M
December 31, 2022
September 30, 2022 72.95M
June 30, 2022 0.00
March 31, 2022 -2.582M
December 31, 2021 1.295M
Date Value
September 30, 2021 0.054M
June 30, 2021 0.223M
March 31, 2021 0.136M
December 31, 2020 69.44M
September 30, 2020 13.13M
June 30, 2020 -0.0056M
March 31, 2020 0.1648M
December 31, 2019 0.468M
September 30, 2019 70.21M
June 30, 2019 -0.0055M
March 31, 2019 77.57M
December 31, 2018 -0.0071M
September 30, 2018 -1.422M
June 30, 2018 89.07M
March 31, 2018 42.40M
December 31, 2017
September 30, 2017 10.02M
June 30, 2017 -0.0017M
March 31, 2017 0.1965M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Xencor, Inc. 1.031M
UroGen Pharma Ltd. 2.186M
Ironwood Pharmaceuticals, Inc. -199.70M
Viking Therapeutics, Inc. 23.59M
IDEAYA Biosciences, Inc. 359.21M